The development of vaccines for prevention of diseases caused by pathogenic species can
encounter major obstacles if high sequence diversity is observed between individual strains …

There is currently no Lyme borreliosis vaccine available for humans, although it has been
shown that the disease can be prevented by immunization with an OspA-based vaccine …

Background For clinical development of a novel multivalent OspA vaccine against Lyme
borreliosis, serological assays are required which can be used to establish immune …

SmithKlineBeecham(LYMErix) was licensed for human use in 1998. However, a non-
substantiated hypothesis that LYMErix triggered arthritis in some vaccine recipients [5, 6] …

We have previously shown that the Outer surface protein A (OspA) based Lyme borreliosis
vaccine VLA15 induces protective immunity in mice. Herein, we report the induction of …

Editorial no evidence to support this hypothesis. A retrospective study of joint complaints
after vaccination, reported to the Vaccine Adverse Event Reporting System, showed no …

Here, we describe a structure-based approach to reduce the size of an antigen protein for a
subunit vaccine. Our method consists of (i) determining the three-dimensional structure of an …

Lyme borreliosis (LB) is the most common vector-borne disease in the northern hemisphere
and there is no vaccine available for disease prevention. The majority of LB cases in Europe …

Camelid-derived, single-domain antibodies (VHHs) have proven to be extremely powerful
tools in defining the antigenic landscape of immunologically heterogeneous surface …

The three Borrelia species, Borrelia afzelii, Borrelia burgdorferi and Borrelia garinii are the
main species causing the most common tick-borne zoonosis, Lyme borreliosis. By applying …